RetaMaps

Beau'Trez MedSpa Certified Medical-Grade

Beau'Trez MedSpa Certified Medical-Grade · 676 Amboy Avenue · Woodbridge Township, NJ 07095

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • GLP-1 medications named on site
  • Medically supervised weight loss

About this practice

Beau'Trez MedSpa is a medical spa in Woodbridge Township, New Jersey, whose listing shows aesthetics and weight-loss services including semaglutide. Per its website, it takes a holistic approach that connects mind, body and spirit, offering injectables, fillers and facial treatments performed by licensed medical personnel. Because its core offering is spa and aesthetic treatment rather than a dedicated weight-management clinic, anyone considering prescription weight-loss medication here should ask who prescribes it and how visits are supervised. No Google rating or reviews are listed yet.

Services & access

Advertises semaglutide todayYes
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Nearby providers in Woodbridge Township

Nexa Vitality

33 South Wood Avenue · Woodbridge Township, NJ 08830

4.5(20 Google reviews · 1 in past year)

TelehealthAccepts insuranceSemaglutide todayTirzepatide today4 reviews mention GLP-1
View profileVisit website
Listing updated Oct 2, 2026
Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs